DOCSLIB.ORG

編號劑型1 錠劑2 糖漿3 錠劑4 錠劑5 內服顆粒劑6 膠囊劑7 發泡錠8 膠囊劑9 眼用軟膏劑10 注

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
編號劑型1 錠劑2 糖漿3 錠劑4 錠劑5 內服顆粒劑6 膠囊劑7 發泡錠8 膠囊劑9 眼用軟膏劑10 注 獸醫師專案申請人用藥品治療動物之暫行替代品項(第二次公告) 109年09月24日 編號 主成份 劑型 備註 1 ACARBOSE 錠劑 2 ACETAMINOPHEN 糖漿 3 ACETAMINOPHEN (EQ TO PARACETAMOL) 錠劑 4 ACETAZOLAMIDE 錠劑 5 ACETYLCYSTEINE 內服顆粒劑 6 ACETYLCYSTEINE 膠囊劑 7 ACETYLCYSTEINE 發泡錠 8 ACITRETIN 膠囊劑 9 ACYCLOVIR 眼用軟膏劑 10 ACYCLOVIR 注射劑 11 ACYCLOVIR 乳膏劑/軟膏劑 12 ACYCLOVIR 懸液劑 13 ACYCLOVIR 錠劑 14 ADENOSINE 注射劑 15 ADRENALIN 注射劑 16 ALBUMIN SERUM 注射劑 17 ALBUMIN TANNATE (TANNALBIN) 錠劑 18 ALENDRONATE 錠劑 19 ALLOPURINOL 錠劑 20 ALLOPURINOL 膠囊劑 21 ALPHA-CHYMOTRYPSIN 錠劑 22 ALPHA-CHYMOTRYPSIN 陰道錠 ALUMINUM HYDROXIDE DRIED GEL , MAGNESIUM 23 錠劑 HYDROXIDE ALUMINUM HYDROXIDE MAGNESIUM CARBONATE 24 CO-DRIDE GEL, MAGNESIUM HYDROXIDE, 錠劑 SIMETHICONE (ACTIVE DIMETHICON 不得使用於禽 25 AMANTADIN HCL 錠劑 類 XYLITOL, L-ALANINE, ARGININE HCL L-, L- ASPARTIC ACID, L-CYSTEINE, CYSTEINE L- HCL (EQ TO L-CYSTEINE HYDROCHLORIDE), GLUTAMIC ACID L-, HISTIDINE L- HCL (EQ TO L-HISTIDINE HYDROCHLORIDE), L-ISOLEUCINE, L-LEUCINE, 26 注射劑 LYSINE L- HCL ( EQ TO L-LYSINE HCL), LMETHIONINE, L-PHENYLALANINE, L-PROLINE, L- SERINE, L-THREONINE, L-TRYPTOPHAN, LTYROSINE, L-VALINE, GLYCINE (EQ TO AMINOACETIC ACID)(EQ TO GLYCOCOLL) 27 AMIODARONE HCL 錠劑 28 AMIODARONE HCL 注射劑 29 AMITRIPTYLINE 錠劑 30 AMITRIPTYLINE 糖衣錠 31 AMLODIPINE BESYLATE 錠劑 32 AMPHOTERICIN B 凍晶注射劑 33 AMPHOTERICIN B 乾粉注射劑 34 ANETHOLE TRITHIONE 糖衣錠 35 ANTIVENIN OF D.RUSSELLII 注射劑 36 ANTIVENIN of Tr. Mucrosquamatus & Tr. Gramineus 注射劑 37 APOMORPHINE HCL 針劑 38 ARGIPRESSIN (=8-ARGI 20iu/ml 注射劑 39 ASCORBIC ACID 注射劑 40 ASVERIN (TIPEPIDINE HIBENZATE) 內服顆粒劑 41 ATENOLOL 膜衣錠 42 CISATRACURIUM 注射劑 43 ATROPINE SULFATE 點眼膏劑 44 ATROPINE SULFATE 錠劑 ATROPINE SULFATE,HYOSCYAMINE 45 錠劑 SULFATE,SCOPOLAMINE HBR,PHENOBARBITAL 46 AZAPENTACENE POLYSULFONATE SODIUM 點眼液劑 47 AZATHIOPRINE 膜衣錠 B. MULTICINCTUS ANTIVENIN BIVALENT, N. NAJA 48 注射劑 ATRA ANTIVENIN 49 Baclofen 10.0MG (BACLOFEN) 錠劑 BELLADONNA LEAF ALKALOID, ERGOTAMINE 50 糖衣錠 TARTRATE, PHENOBARBITAL 51 BENPROPERINE 錠劑 52 BETAMETHASONE 錠劑 53 BETAMETHASONE 4mg/ml/10ml 注射劑 BETAMETHASONE SODIUM +BETAMETHASONE 54 注射劑 ACETATE 55 BETAXOLOL HCl 點眼懸液劑 Bifidobacterium bifidum , Streptococcus faecalis , 56 錠劑 Lactobacillus acidophilus 57 BISACODYL 錠劑 58 BISACODYL 栓劑 59 BRINZOLAMIDE +TIMOOL MALEATE 點眼懸液劑 60 BROMHEXINE HCL 內服液劑 61 BROMHEXINE HCL 糖漿用顆粒劑 62 BUDESONIDE 噴液劑 63 BUPIVACAINE HCL 注射劑 64 BUSPIRONE HCL (Buspar) 錠劑 65 BUSULFAN 膜衣錠 BUTYLSCOPOLAMINE BROMIDE (EQ TO HYOSCINE- 66 糖衣錠 N-BUTYLBROMIDE) CITRULLINE L-, ARGININE HCL L-, ORNITHINE L- 67 注射劑 HCL 68 CABERGOLINE 錠劑 69 CALCITONIN SALMON 注射劑 70 CALCITRIOL 膠囊劑/軟膠囊劑 71 CALCIUM ACETATE 錠劑 72 CALCIUM +D3 膜衣錠 73 CARBAMAZEPINE 錠劑 74 CARBAMAZEPINE 口服液 75 CARBACHOL 點眼液劑 76 CARBIMAZOLE 錠劑 77 CARBOCYSTEINE 錠劑 78 CARBOMER (CARBOXYPOLYMETHYLENE) 眼用凝膠劑 79 CARBOPLATIN 注射劑 80 DILTIAZEM 錠劑 81 L-CARNITINE INNER SALT 咀嚼錠 82 CARTEOLOL HCL 點眼液劑 83 CARVEDILOL 錠劑 84 CASPOFUNGIN (ACETATE 凍晶注射劑 85 CENTRUM JUNIOR (小善存) 錠劑 86 CETIRIZINE 2HCl 膜衣錠 87 CHARCOAL 顆粒劑 88 CHLORAMBUCIL 膜衣錠 89 CHLORPHENIRAMINE MALEATE 錠劑 CHLORPHENIRAMINE MALEATE, ACETAMINOPHEN (EQ TO PARACETAMOL), ALUMINUM BIS(ACETYLSALICYLATE)(ALUMINUM 90 ACETYLSALICYLA, ETHENZAMIDE 糖衣錠 (ETHOXYBENZAMIDE), CAFFEINE ANHYDROUS, NOSCAPINE, POTASSIUM GUAIACOLSULFONATE, THIAMINE MONONITRATE, RIBOFLAVIN (VIT B2) CHLORPHENIRAMINE MALEATE, BIOTIN, NIACINAMIDE (NICOTINAMIDE), RIBOFLAVIN (VIT 91 B2), PYRIDOXINE HCL, PANTOTHENATE CALCIUM, 錠劑 GLYCYRRHIZINIC ACID (EQ TO GLYCYRRHETINIC ACID GLYCOSIDE)(EQ TO GLYCYRRHIZIC ACID ) CHLORPHENIRAMINE MALEATE, LIDOCAINE HCL, 92 HEXACHLOROPHENE, CAMPHOR, MENTHOL, 軟膏劑 METHYL SALICYLATE CHLORPHENIRAMINE MALEATE, METHIONINE DL-, PANTHENOL, BIOTIN, NIACINAMIDE 93 (NICOTINAMIDE), FLAVINEADENINE 注射劑 DINUCLEOTIDE, RIBOFLAVIN PHOSPHATE, PYRIDOXINE HCL CHLORPHENIRAMINE MALEATE, SODIUM CHLORIDE, BIOTIN, RIBOFLAVIN (VIT B2), 94 注射劑 PYRIDOXINE HCL, GLYCYRRHIZATE AMMONIUM SALT (GLYCAMIL) 95 CHLORPROMAZINE HCL 糖衣錠 96 CHLORPROMAZINE HCL 錠劑 97 CHLORPROMAZINE HCL 注射劑 98 CHLORZOXAZONE 錠劑 CHOLINE CHLORIDE, SODIUM THIOSULFATE, NIACINAMIDE (NICOTINAMIDE), THIAMINE (VITAMIN B1), RIBOFLAVIN (VIT B2), 99 注射劑 PYRIDOXINE(VITAMIN B6), SODIUM PANTOTHENATE, INOSITOL (MESOINOSITOL), BENZYL ALCOHOL 100 CILAZAPRIL 膜衣錠 101 CISPLATIN 注射劑 102 CLEMASTINE FUMARATE 錠劑 103 CLOMIPRAMINE HCL 膜衣錠 104 CLOMIPRAMINE HCL 糖衣錠 105 CLONIDINE HCL 錠劑 106 CLOPIDOGREL HYDROGEN SULFATE 錠劑 107 CLOPIDOGREL BISULFATE 膜衣錠 108 COLCHICINE 錠劑 109 CROMOLYN SODIUM 點眼液劑 110 CYANOCOBALAMIN (1MG/ML) 注射劑 111 CYCLOPENTOLATE HCL 1% 點眼液劑 112 CYCLOPHOSPHAMIDE 糖衣錠 113 CYCLOPHOSPHOMIDE 注射劑 114 CYCLOSPORIN 軟膠囊劑 115 CYCLOSPORIN 內服液劑 116 CYCLOSPORIN 靜脈注射針劑 117 DALTEPARIN SODIUM 注射劑 118 DANTROLENE 注射劑 119 DANTROLENE SODIUM 膠囊劑 120 SELEGILINE HYDROCHLORIDE 錠劑 121 DESFERRIOXAMINE MESYLATE 凍晶注射劑 122 DESMOPRESSIN ACETATE 注射劑 123 DESMOPRESSIN ACETATE 錠劑 124 Dexamethasone 錠劑 125 Dexamethasone 點眼液劑 126 DEXMEDETOMIDINE HYDROCHLORIDE 注射劑 127 Dextrose , Sodium chloride 注射劑 DEXTROSE MONOHYDRATE, METHIONINE DL-, NIACINAMIDE (NICOTINAMIDE), THIAMINE 128 HYDROCHLORIDE, RIBOFLAVIN(5'-PHOSPHATE 注射劑 SODIUM), TAURINE (EQ TO 2-AMINOETHANE SULFONIC ACID) DEXTROSE MONOHYDRATE200mg+METHIONINE DL- 20mg +THIAMINE 129 注射劑 HYDROCHLORIDE250mg+RIBOFLAVIN0.1mg(5'- PHOSPHATE SODIUM) /ml DEXTROSE, PANTHENOL D- (EQ TO D-PANTHENOL), NIACINAMIDE (NICOTINAMIDE), THIAMINE 130 注射劑 HYDROCHLORIDE, RIBOFLAVIN (VIT B2), PYRIDOXINE HCL, ASCORBIC ACID (VIT C) DIASTASE ASPERGILLUS ORYZAE(DIASTASE TAKA), 131 LIPASE, PANCREATIN (DIASTASE VERA), LACTOMIN, 錠劑 YEAST (TORULA YEAST), THIAMINE (VITAMIN B1) 132 Diclofenac sodium 點眼液劑 133 Diclofenac Sodium 糖衣錠 134 Diclofenac Sodium 注射劑 135 Diclofenac Sodium 膠囊劑 136 Diclofenac Sodium 錠劑 137 Diclofenac Sodium 栓劑 138 Diclofenac Sodium 凝膠 139 Diclofenac Sodium 乳膠劑 140 DIGOXIN 酏劑 141 DIHYDROXYPROPYL THEOPHYLLINE 注射劑 142 DIMENHYDRINATE 錠劑 DIMETHICONE (EQ TO DIMETHYLPOLYSILOXANE 143 錠劑 OR POLYDIMETHYL SILOXANE) 144 DIPHENHYDRAMINE 錠劑 145 DIPHENIDOL HCl 糖衣錠 146 DISOPYRAMIDE 膠囊劑 147 DOCETAXEL 注射劑 148 DOMPERIDONE 錠劑 149 DORZOLAMIDE HCL 2% 點眼液劑 150 EDETATE CALCIUM DISODIUM 注射劑 151 EMEDASTINE (AS DIFUMARATE) 點眼液劑 152 ENOXAPARIN SODIUM 注射劑 153 EPIRUBICIN HCL 注射劑 154 Epoetin alfa 針劑 155 EPOETIN BETA (GENETI 注射劑 156 EPRAZINONE 2HCL 錠劑 157 ERGONOVINE 錠劑 158 ERGONOVINE 注射劑 159 ESMOLOL HYDROCHLORIDE 注射劑 160 ESOMEPRAZOLE MAGNESIUM TRIHYDRATE 錠劑 161 ESTRADIOL-17-CYCLOPE 注射劑 162 ETANERCEPT 注射劑 163 ETODOLAC 膠囊 164 ETODOLAC 錠劑 165 FAMCICLOVIR 膜衣錠 FERROUS (SULFATE), THIAMINE MONONITRATE, 166 RIBOFLAVIN (VIT B2), CYANOCOBALAMIN (VIT B12), 糖衣錠 FOLIC ACID, ASCORBIC ACID (VIT C) 167 FERROUS SULFATE 糖衣錠 168 FILGRASTIM 注射劑 169 FINASTERIDE 錠劑 170 FLAVOXATE HCL 錠劑 171 FLUCONAZOLE 錠劑 172 FLUCONAZOLE 靜脈點滴注 173 FLUCONAZOLE 膠囊劑 174 FLUCONAZOLE 注射劑 175 FLUDROCORTISONE 錠劑 176 FLUMAZENIL 注射劑 177 FLUMETHASONE PIVALATE 軟膏 178 FLUOROURACIL 注射劑 179 FLUOROURACIL 軟膏劑 180 FLUOXETINE (HYDROCHLORIDE) 膠囊劑 181 FLUTICASONE PROPIONA 氣化噴霧用 182 FLUTICASONE PROPIONA 口腔吸入劑 183 FOLIC ACID 錠劑 GAMMA ORYZANOL, CALCIUM LACTATE HYDRATE, FURSULTIAMINE HYDROCHLORIDE, PYRIDOXINE 184 HYDROCHLORIDE, CYANOCOBALAMIN (VIT B12), 糖衣錠 Calcium Pantothenate, CALCIUM PANTOTHENATE TYPE S, TOCOPHEROL CALCIUM SUCCINATE 185 GABAPENTIN 膠囊劑 186 GABAPENTIN 膜衣錠 187 GABEXATE MESILATE 凍晶注射劑 ALUMINUM HYDROXIDE DRIED GEL, MAGNESIUM 188 錠劑 HYDROXIDE, MAGNESIUM TRISILICATE 189 GEMCITABINE HYDROCHL 凍晶注射劑 190 GEMFIBROZIL 膜衣錠 191 GEMFIBROZIL 膠囊 192 GINKGO BILOBA FOLIUM EXTRACT 膜衣錠 193 GLIMEPIRIDE 錠劑 194 GLIMEPIRIDE + METFORMIN HCL 錠劑 195 GLIPIZIDE 錠劑 196 GLUCAGON 注射劑 197 GLYBURIDE (=GLIBENCL 錠劑 198 GLYCOPYRROLATE 注射劑 199 GLYCOPYRROLATE 錠劑 200 GONADOTROPIN CHORION 凍晶注射劑 201 GRANISETRON HCl 1mg/ml 注射劑 202 GRISEOFULVIN 錠劑 203 GUAIACOL GLYCERYL ET 內服液劑 GUAIACOL GLYCERYL ETHER (EQ TO 204 GUAIFENESIN), THEOPHYLLINE SODIUM 錠劑 GLYCINATE 205 HALOPERIDOL 錠劑 206 HALOPERIDOL (DECANOATE) 注射劑 207 HEPARIN SODIUM 軟膏劑/乳膏劑 SODIUM LACTATE, CALCIUM CHLORIDE, 208 POTASSIUM CHLORIDE, SODIUM CHLORIDE, 注射劑 GLUCOSE, HYDROXYETHYL STARCH 70000 209 HETASTARCH, SODIUM CHLORIDE 注射劑 210 HYDRALAZINE HCL 錠劑 211 HYDRALAZINE HCL 注射劑 212 HYDRALAZINE HCL 糖衣錠 HYDRALAZINE HCL, RESERPINE, 213 糖衣錠 HYDROCHLOROTHIAZIDE 214 HYDROCORTISONE 外用液劑 215 HYDROCORTISONE (SODIUM SUCCINATE) 凍晶注射劑 216 HYDROCORTISONE 乳膏劑 217 HYDROCORTISONE 17-BUTYRATE 軟膏劑 218 HYDROCORTISONE 500MG 注射劑 HYDROCORTISONE ACETATE OPHTHALMIC 219 點眼液劑 SUSPENSION 0.5% 220 HYDROCORTISONE+POVIDONE-IODINE 軟膏劑 221 HYDROGEN PEROXIDE 外用液劑 222 HYDROXYETHYL STARCH 注射劑 223 HYDROXYUREA 膠囊劑 224 HYDROXYZINE HCL 錠劑 225 HYDROXYZINE PAMOATE 膠囊劑 226 HYOSCYAMINE SULFATE 錠劑 227 IBUPROFEN LYSINE 注射劑 228 IFOSFAMIDE 注射劑 229 IMIPRAMINE HCL 糖衣錠 230 IMIPRAMINE HCL 膜衣錠 231 MALTOSE, Human Immunoglobulin G 注射劑 232 IOPAMIDOL 注射劑 233 IPRATROPIUM BROMIDE 吸入用液劑 234 IRBESARTAN 膜衣錠劑 235 ISOPROPYL UNOPROSTONE 點眼液劑 236 ISOTRETINOIN 軟膠囊劑 237 ITRACONAZOLE 內服液劑 238 ITRACONAZOLE 注射劑 239 ITRACONAZOLE 膠囊劑 240 KETOCONAZOLE 洗髮劑 241 KETOCONAZOLE 乳膏劑 242 KETOCONAZOLE 錠劑 備註1 243 KETOPROFEN 膠囊劑 244 KETOPROFEN 外用凝膠劑 245 KETOPROFEN 注射劑 246 KETOROLAC TROMETHAMINE 膜衣錠 247 KETOROLAC TROMETHAMINE 注射劑 248 KETOROLAC TROMETHAMINE 點眼液 249 Lactose Ringer solution 注射劑 250 Lactulose , Galactose 液劑 251 LANTHANUM CARBONATE 咀嚼錠 252 L-ASPARAGINASE 凍晶注射劑 253 LATANOPROST 點眼液劑 254 LEFLUNOMIDE 錠劑 255 LEUCOVORIN CALCIUM (ANHYDRIDE) 注射劑 256 LEVAMISOLE (HCL) 150MG/TAB 錠劑 257 LEVETIRACETAM 內服液劑 258 LEVETIRACETAM 膜衣錠 259 LEVETIRACETAM 注射劑 260 LEVOBUNOLOL HCL 點眼液劑 261 LEVOTHYROXINE SODIUM 錠劑 262 GONADORELIN ACETATE 注射劑 LIPASE, PANCREATIN (DIASTASE VERA), PEPSIN 263 膠囊劑 SACCHARATED 264 LISINOPRIL 錠劑 265 LOPERAMIDE HCl 膠囊劑 LYSOZYME CHLORIDE, DEXTROMETHORPHAN HBR, 266 膠囊劑 POTASSIUM CRESOLSULFONATE LYSOZYME CHLORIDE, CHLORHEXIDINE HCL, 267 GLYCYRRHIZINATE DIPOTASSIUM (EQ TO 口含錠 DIPOTASSIUM
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
    Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%).
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Nippon AMR One Health Report (NAOR) 2019
    Nippon AMR One Health Report (NAOR) 2019 November 27, 2019 The AMR One Health Surveillance Committee TABLE OF CONTENTS Preface .................................................................................................................................................................... 1 Abbreviations ......................................................................................................................................................... 2 Types and Abbreviations of Antimicrobials ........................................................................................................... 3 Executive Summary ................................................................................................................................................ 6 Outcome Indices for the Action Plan...................................................................................................................... 9 Current Status of Antimicrobial-resistant Bacteria in Japan ................................................................................. 10 (1) Humans ......................................................................................................................................................................... 11 1) Gram-negative bacteria ................................................................................................................................................. 11 2) Gram-positive bacteria .................................................................................................................................................
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel Et Al
    USOO698.6901B2 (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel et al. (45) Date of Patent: Jan. 17, 2006 (54) GASTROINTESTINAL COMPOSITIONS 6,121,301 A 9/2000 Nagasawa et al. 6,127,418 A 10/2000 Bueno et al. (75) Inventors: Gerard M. Meisel, Budd Lake, NJ 6,156,771. A 12/2000 Rubin et al. S. Arthur A. Ciociola, Far Hills, NJ FOREIGN PATENT DOCUMENTS CA 967977 5/1975 (73) Assignee: Warner-Lambert Company LLC, CA 2136164 3/1995 Morris Plains, NJ (US) CN 1092314 3/1993 CN 1118267 5/1994 (*) Notice: Subject to any disclaimer, the term of this DE 9859.499 : 12/1998 patent is extended or adjusted under 35 E. O S. A1 3.10: U.S.C. 154(b) by 234 days. FR 2244469 8/1973 FR 4506 8/1993 (21) Appl. No.: 10/196,053 FR 277 1009 11/1997 JP 56128719 3/1980 (22) Filed: Jul. 15, 2002 JP 306.6627 8/1989 O O JP 9052829 6/1995 (65) Prior Publication Data WO WO 95.01803 A1 * 1/1995 US 2004/0013741 A1 Jan. 22, 2004 WO WO 9725,979 1/1996 WO WOOO765OO 12/2000 (51) Int. Cl. WO WOO121601 3/2001 A6IF I3/00 (2006.01) ZA 61O1840 8/1993 A6F 99.6A06 3032006.O1 OTHER PUBLICATIONS A6 IK 948 (2006.01) JW Read, JL Abitbol, KD Bardhan, PJ Whorwell, B Fraitag-"Efficacy and Safety of the peripheral kappa ago (52) U.S. Cl. ....................... 424/436; 424/422; 424/430; nist fedotoZine verSuS placebo in the treatment of functional 424/433; 424/451; 424/464; 424/489 dyspepsia see comments)." Gut Nov., 1997 41(5):664-8.
    [Show full text]
  • Probiotics for Treating Infectious Diarrhoea (Review)
    Probiotics for treating infectious diarrhoea (Review) Allen SJ, Okoko B, Martinez EG, Gregorio GV, Dans LF This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1 http://www.thecochranelibrary.com Probiotics for treating infectious diarrhoea (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 5 DISCUSSION ..................................... 9 AUTHORS’CONCLUSIONS . 10 ACKNOWLEDGEMENTS . 10 REFERENCES ..................................... 10 CHARACTERISTICSOFSTUDIES . 14 DATAANDANALYSES. 31 Analysis 1.1. Comparison 1 Probiotic versus control, Outcome 1 Diarrhoea lasting 3 or more days. 35 Analysis 1.2. Comparison 1 Probiotic versus control, Outcome 2 Diarrhoea lasting 4 or more days. 37 Analysis 1.3. Comparison 1 Probiotic versus control, Outcome 3 Mean duration of diarrhoea (hours). 39 Analysis 1.4. Comparison 1 Probiotic versus control, Outcome 4 Mean stool frequency on day 2. 40 Analysis 1.5. Comparison 1 Probiotic versus control, Outcome 5 Mean stool frequency on day 3. 41 Analysis 2.1. Comparison 2 Sensitivity analysis; diarrhoea lasting 3 or more days, Outcome 1 Generation of allocation sequence. ................................... 42 Analysis 2.2. Comparison 2 Sensitivity analysis; diarrhoea lasting 3 or more days, Outcome 2 Allocation concealment. 43 Analysis 2.3. Comparison 2 Sensitivity analysis; diarrhoea lasting 3 or more days, Outcome 3 Blinding. 45 Analysis 2.4. Comparison 2 Sensitivity analysis; diarrhoea lasting 3 or more days, Outcome 4 Follow up. 46 Analysis 3.1. Comparison 3 Sensitivity analysis: diarrhoea lasting 4 or more days, Outcome 1 Generation of allocation sequence.
    [Show full text]
  • Page 1 FINLANDS FÖRFATTNINGSSAMLING Utgiven I Helsingfors
    FINLANDS FÖRFATTNINGSSAMLING MuuMnrovvvvBeslutom läkemedelsförteckning asia av Säkerhets- och utvecklingscentret för läkemedelsområdet Utgiven i Helsingfors den 23 mars 2016 201/2016 Beslut av Säkerhets- och utvecklingscentret för läkemedelsområdet om läkemedelsförteckning Säkerhets- och utvecklingscentret för läkemedelsområdet har med stöd av 83 § i läke- medelslagen av den 10 april 1987 (395/1987) beslutat fastställa följande läkemedelsför- teckning: 1§ Förteckningens syfte Föreliggande beslut innehåller en förteckning över ämnen och droger som används medicinskt i Finland. Läkemedelsförteckningen upprättas med beaktande av bestämmel- serna i 3 och 5 § i läkemedelslagen. Med läkemedel avses ett preparat eller ämne vars ändamål är att vid invärtes eller ut- värtes bruk bota, lindra eller förebygga sjukdomar eller sjukdomssymtom hos människor eller djur. Som läkemedel betraktas också ett sådant ämne eller en sådan kombination av ämnen för invärtes eller utvärtes bruk som kan användas för att genom farmakologisk, im- munologisk eller metabolisk verkan återställa, korrigera eller modifiera fysiologiska funk- tioner eller utröna hälsotillståndet eller sjukdomsorsaker hos människor eller djur. Läkemedelsförteckningen är inte uttömmande. Till läkemedel räknas även sådana äm- nen och droger som inte nämns i denna förteckning men som uppfyller definitionen av lä- kemedel i läkemedelslagen. Utöver fastställande av läkemedelsförteckningen beslutar Säkerhets- och utvecklings- centret för läkemedelsområdet med stöd av 6 § i läkemedelslagen vid behov om ett ämne eller ett preparat ska betraktas som ett läkemedel. Centret beslutar separat i respektive fall om ett preparat som innehåller ett ämne i förteckningen ska betraktas som ett läkemedel med beaktande av produktens framställningssätt, sammansättning, dess farmakologiska egenskaper, hur det används, dess spridning, hur känt det är hos konsumenterna och de ris- ker som kan vara förenade med dess användning.
    [Show full text]
  • Säädk 415/2019
    SUOMEN SÄÄDÖSKOKOELMA MuuMnrovvvvLääkealanlääkeluettelosta asia turvallisuus- ja kehittämiskeskuksen päätös Julkaistu Helsingissä 29 päivänä maaliskuuta 2019 415/2019 Lääkealan turvallisuus- ja kehittämiskeskuksen päätös lääkeluettelosta Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääkelain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1§ Luettelon tarkoitus Tämä päätös sisältää luettelon Suomessa lääkkeellisessä käytössä olevista aineista ja rohdoksista. Lääkeluettelo laaditaan ottaen huomioon lääkelain 3 §:n ja 5 §:n säännökset. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ul- koisesti käytettynä parantaa, lievittää tai ehkäistä sairautta tai sen oireita ihmisessä tai eläi- messä. Lääkkeeksi katsotaan myös sisäisesti tai ulkoisesti käytettävä aine tai aineiden yh- distelmä, jota voidaan käyttää ihmisen tai eläimen elintoimintojen palauttamiseksi, kor- jaamiseksi tai muuttamiseksi farmakologisen, immunologisen tai metabolisen vaikutuk- sen avulla taikka terveydentilan tai sairauden syyn selvittämiseksi. Lääkeluettelo ei ole tyhjentävä. Tässä luettelossa mainitsemattomat aineet ja rohdokset, jotka täyttävät lääkelain lääkkeen määritelmän, ovat lääkkeitä. Lääkeluettelon vahvistamisen lisäksi Lääkealan turvallisuus- ja kehittämiskeskus päättää lääkelain 6 §:n nojalla tarvittaessa, onko ainetta tai valmistetta pidettävä lääkkeenä. Keskus päättää tapauskohtaisesti onko luettelossa olevaa ainetta sisältävää valmistetta pidettävä lääk- keenä
    [Show full text]
  • Supplement Ii to the Japanese Pharmacopoeia Seventeenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION O‹cial from June 28, 2019 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. Printed in Japan The Ministry of Health, Labour and Welfare Ministerial Notification No. 49 Pursuant to Paragraph 1, Article 41 of Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145, 1960), this notification stated that a part of the Japanese Pharmacopoeia was revised as follows*. NEMOTO Takumi The Minister of Health, Labour and Welfare June 28, 2019 A part of the Japanese Pharmacopoeia (Ministerial Notification No. 64, 2016) was revised as follows*. (The text referred to by the term ``as follows'' are omitted here. All of the revised Japanese Pharmacopoeia in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'' in Supplement 2) are made available for public exhibition at the Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmen- tal Health Bureau, Ministry of Health, Labour and Welfare, at each Regional Bureau of Health and Welfare, and at each Prefectural Office in Japan). Supplementary Provisions (Effective Date) Article 1 This Notification is applied from June 28, 2019. (Transitional measures) Article 2 In the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as ``previous Pharmacopoeia'') [limited to those listed in new Pharmacopoeia] and drugs which have been approved as of June 28, 2019 as prescribed under Paragraph 1, Article 14 of Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No.
    [Show full text]